News

Filter

1 to 9 of 23 results

Regado and Tobira to merge to create leading NASH company

Regado and Tobira to merge to create leading NASH company

14-01-2015

The USA’s Regado Biosciences and privately-held Tobira Therapeutics have entered into a definitive…

Mergers & AcquisitionsNephrology and HepatologyPharmaceuticalRegadoTobira TherapeuticsUSA

CVS to cover Gilead’s hepatitis C drugs Harvoni and Sovaldi exclusively

CVS to cover Gilead’s hepatitis C drugs Harvoni and Sovaldi exclusively

06-01-2015

US pharmacy benefits manager CVS Health has entered into a deal with US biotech major Gilead Sciences…

GileadHarvoniNephrology and HepatologyPharmaceuticalPricingSovaldiUSA

Achillion shares jump on positive interim results from ACH-3102 and ACH-322 for hepatitis C

Achillion shares jump on positive interim results from ACH-3102 and ACH-322 for hepatitis C

23-12-2014

US pharma company Achillion Pharmaceuticals saw its shares jump as much as 60% on the announcement of…

ACH-3102ACH-3422Achillion PharmaceuticalsNephrology and HepatologyPharmaceuticalResearchUSA

Merck's Phase II trial of grazoprevir/elbasvir in hepatitis C genotype 1 positive

Merck's Phase II trial of grazoprevir/elbasvir in hepatitis C genotype 1 positive

12-11-2014

Pharma giant Merck & Co has presented results from its Phase II trial of grazoprevir/elbasvir, with or…

grazoprevir/elbasvirMerck & CoNephrology and HepatologyPharmaceuticalResearchUSA

Islet Sciences announces merger with Brighthaven Ventures

Islet Sciences announces merger with Brighthaven Ventures

01-10-2014

Metabolic biopharma specialist Islet Sciences has announced a merger with Brighthaven Ventures, a privately-held…

Islet SciencesMergers & AcquisitionsNephrology and HepatologyPharmaceuticalremogliflozinUSA

Achillion a good candidate for collaboration or takeover based on hepatitis C candidate, says Edison

Achillion a good candidate for collaboration or takeover based on hepatitis C candidate, says Edison

29-09-2014

Achillion Pharmaceuticals is in a prime position to develop its own all-oral hepatitis C treatment as…

Achillion PharmaceuticalsFinancialMarkets & MarketingNephrology and HepatologyPharmaceuticalUSA

OPKO's second Rayaldee Ph III trial meets primary endpoints

OPKO's second Rayaldee Ph III trial meets primary endpoints

24-09-2014

US drugmaker OPKO Health has released successful top-line results from the second and final pivotal Phase…

Nephrology and HepatologyOPKO HealthPharmaceuticalRayaldeeResearchUSA

Keryx' shares fall as FDA approves kidney drug, but with warnings

Keryx' shares fall as FDA approves kidney drug, but with warnings

07-09-2014

US drugmaker Keryx Biopharmaceuticals has received approval from the US Food and Drug Administration…

ferric citrateKeryx BiopharmaceuticalsNephrology and HepatologyPharmaceuticalRegulationRenvelaSanofiUSAZerenex

1 to 9 of 23 results

COMPANY SPOTLIGHT

Menarini

Back to top